Immuneering Corporation announced that the United States Patent and Trademark Office has granted a composition of matter patent for their cancer drug candidate, atebimetinib (IMM-1-104). This newly issued patent is expected to provide exclusivity until 2042, with the potential for patent term extension. Atebimetinib is an oral once-daily deep cyclic inhibitor of MEK, designed to provide a longer-lasting benefit by overcoming resistance mechanisms in cancer treatment. Additional patent applications for atebimetinib related to compounds, pharmaceutical compositions, and methods of use are pending, with expected expiration into 2044. The company has observed promising results in first-line pancreatic cancer patients, noting exceptional durability and favorable tolerability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.